Rola zbilansowanej suplementacji w diecie chorych ze zwyrodnieniem plamki związanym z wiekiem Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 15, 2021
Słowa kluczowe:
AMD, witaminy, minerały, karotenoidy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Cel: Celem pracy było omówienie roli zbilansowanej suplementacji w diecie chorych ze zwyrodnieniem plamki związanym z wiekiem (AMD, age-related macular degeneration).
Metody: Dokonano przeglądu piśmiennictwa z ostatnich lat dotyczącego roli witamin: D, C, E, B6, B12, cynku, luteiny, zeaksantyny, kwasu omega-3 oraz kwasu foliowego w prewencji AMD.
Wyniki: Witaminy, składniki mineralne i karotenoidy są niezbędne do prawidłowego funkcjonowania siatkówki, ponieważ modulują odpowiedź zapalną i immunologiczną.
Wnioski: Omówione w pracy witaminy, minerały oraz karotenoidy mają właściwości przeciwzapalne oraz przeciwutleniające, dzięki czemu zmniejszają ryzyko progresji AMD. W związku z powyższym należy zapewnić właściwe stężenie tych substancji w diecie pacjentów z AMD.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Kusz vel Sobczuk I, Święch A. Rola zbilansowanej suplementacji w diecie chorych ze zwyrodnieniem plamki związanym z wiekiem. Ophthatherapy [Internet]. 15 marzec 2021 [cytowane 3 lipiec 2024];8(1):19-5. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1159
Numer
Dział
Terapie zachowawcze
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Kauppinen A, Paterno JJ, Blasiak J et al. Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci. 2016; 73: 1765-86.
2. Klein R, Klein BE, Tomany SC et al. Ten-year incidence of age-related maculopathy and smoking and drinking: The Beaver Dam Eye Study. Am J Epidemiol. 2002; 156: 589-98.
3. Alsalem JA, Patel D, Susarla R et al. Characterization of Vitamin D Production by Human Ocular Barrier Cells. Invest Ophthalmol Vis Sci. 2014; 55(4): 2140-7.
4. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2012; 76: 315-25.
5. Jeffery LE, Burke F, Mura M et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009; 183: 5458-67.
6. Bartels LE, Hvas CL, Agnholt J et al. Human dendritic cell antigen presentation and chemotaxis are inhibited by intrinsic 25-hydroxy vitamin D activation. Int Immunopharmacol. 2010; 10: 922-8.
7. Kaarniranta K, Pawlowska E, Szczepanska J et al. Can vitamin D protect against age-related macular degeneration or slow its progression? Acta Biochim Pol. 2019; 66(2): 147-58.
8. Millen AE, Meyers KJ, Liu Z et al. Association between vitamin D status and age-related macular degeneration by genetic risk. JAMA Ophthalmol. 2015; 133(10): 1171-9.
9. Rusińska A, Płudowski P, Walczak M et al. Vitamin D Supplementation Guidelines for General Population and Groups at Risk of vitamin D Deficiency in Poland – Recommendations of the Polish Society of Pediatric endocrinology and Diabetes and the expert Panel with Participation of National Specialist Consultants and Representatives of Scientific Societies – 2018 Update. Front Endocrinol (Lausanne). 2018; 9: 246.
10. Li LH, Chung-Yung Lee J, Hang Leung H et al. Lutein Supplementation for Eye Diseases. Nutrients. 2020; 12(6): 1721.
11. Renzi LM, Hammond BR Jr, Dengler M et al. The relation between serum lipids and lutein and zeaxanthin in the serum and retina: Results from cross-sectional, case-control and case study designs. Lipids Health Dis. 2012; 11: 33.
12. Li B, George EW, Rognon GT et al. Imaging lutein and zeaxanthin in the human retina with confocal resonance Raman microscopy. Proc Natl Acad Sci USA. 2020; 117: 12352-8.
13. Li SY, Fu ZJ, Lo AC. Hypoxia-induced oxidative stress in ischemic retinopathy. Oxid Med Cell Longev. 2012; 2012: 426769.
14. Junghans A, Sies H, Stahl W. Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Arch Biochem Biophys. 2001; 391: 160-4.
15. Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Ann Rev Nutr. 2003; 23: 171-201.
16. Kijlstra A, Tian Y, Kelly ER et al. Lutein: More than just a filter for blue light. Prog Retin Eye Res. 2012; 31: 303-15.
17. Tian Y, Kijlstra A, Webers CAB et al. Lutein and Factor D: Two intriguing players in the field of age-related macular degeneration. Arch Biochem Biophys. 2015; 572: 49-53.
18. Bian Q, Gao S, Zhou J et al. Lutein and zeaxanthin supplementation reduces photooxidative damage and modulates the expression of inflammation-related genes in retinal pigment epithelial cells. Free Radic Biol Med. 2012; 53: 1298-307.
19. Fung FK, Law BY, Lo AC. Lutein Attenuates Both Apoptosis and Autophagy upon Cobalt (II) Chloride-Induced Hypoxia in Rat Muller Cells. PLoS ONE. 2016; 11: e0167828.
20. Gale CR, Hall NF, Phillips DIW et al. Lutein and Zeaxanthin Status and Risk of Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2003; 44: 2461-5.
21. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA. 2013; 309: 2005-15.
22. Seddon JM, George S, Rosner B. Cigarette Smoking, Fish Consumption, Omega-3 Fatty Acid Intake, and Associations With Age-Related Macular Degeneration The US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol. 2006; 124(7): 995-1001.
23. Seddon JM, Rosner B, Sperduto RD et al. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol. 2001; 119: 1191-9.
24. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004; 11(suppl 1): S56-64.
25. Christen WG, Glynn RJ, Chew EY et al. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women’s Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med. 2009; 169: 335-41.
26. Gopinath B, Flood VM, Rochtchina E et al. Homocysteine, folate, vitamin B-12, and 10-y incidence of age-related macular degeneration. Am J Clin Nutr. 2013; 98(1): 129-35.
27. Christen WG, Glynn RJ, Chew EY et al. Folic Acid, Vitamin B6, and Vitamin B12 in Combination and Agerelated Macular Degeneration in a Randomized Trial of Women. Arch Intern Med. 2009; 169(4): 335-41.
28. Herbert V, Bigaouette J. Call for endorsement of a petition to the Food and Drug Administration to always add vitamin B-12 to any folate fortification or supplement. Am J Clin Nutr. 1997; 65: 572-3.
29. Smailhodzic D, Van Asten F, Blom A et al. Zinc supplementation inhibits complement activation in age-related macular degeneration. PLoS One. 2014; 9(11): e112682.
30. Dharamdasani Detaram H, Mitchell P, Russell J et al. Dietary zinc intake is associated with macular fluid in neovascular age-related macular degeneration. Clin Exp Ophthalmol. 2020; 48(1): 61-8.
31. Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001; 119(10): 1417-36.
2. Klein R, Klein BE, Tomany SC et al. Ten-year incidence of age-related maculopathy and smoking and drinking: The Beaver Dam Eye Study. Am J Epidemiol. 2002; 156: 589-98.
3. Alsalem JA, Patel D, Susarla R et al. Characterization of Vitamin D Production by Human Ocular Barrier Cells. Invest Ophthalmol Vis Sci. 2014; 55(4): 2140-7.
4. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2012; 76: 315-25.
5. Jeffery LE, Burke F, Mura M et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009; 183: 5458-67.
6. Bartels LE, Hvas CL, Agnholt J et al. Human dendritic cell antigen presentation and chemotaxis are inhibited by intrinsic 25-hydroxy vitamin D activation. Int Immunopharmacol. 2010; 10: 922-8.
7. Kaarniranta K, Pawlowska E, Szczepanska J et al. Can vitamin D protect against age-related macular degeneration or slow its progression? Acta Biochim Pol. 2019; 66(2): 147-58.
8. Millen AE, Meyers KJ, Liu Z et al. Association between vitamin D status and age-related macular degeneration by genetic risk. JAMA Ophthalmol. 2015; 133(10): 1171-9.
9. Rusińska A, Płudowski P, Walczak M et al. Vitamin D Supplementation Guidelines for General Population and Groups at Risk of vitamin D Deficiency in Poland – Recommendations of the Polish Society of Pediatric endocrinology and Diabetes and the expert Panel with Participation of National Specialist Consultants and Representatives of Scientific Societies – 2018 Update. Front Endocrinol (Lausanne). 2018; 9: 246.
10. Li LH, Chung-Yung Lee J, Hang Leung H et al. Lutein Supplementation for Eye Diseases. Nutrients. 2020; 12(6): 1721.
11. Renzi LM, Hammond BR Jr, Dengler M et al. The relation between serum lipids and lutein and zeaxanthin in the serum and retina: Results from cross-sectional, case-control and case study designs. Lipids Health Dis. 2012; 11: 33.
12. Li B, George EW, Rognon GT et al. Imaging lutein and zeaxanthin in the human retina with confocal resonance Raman microscopy. Proc Natl Acad Sci USA. 2020; 117: 12352-8.
13. Li SY, Fu ZJ, Lo AC. Hypoxia-induced oxidative stress in ischemic retinopathy. Oxid Med Cell Longev. 2012; 2012: 426769.
14. Junghans A, Sies H, Stahl W. Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Arch Biochem Biophys. 2001; 391: 160-4.
15. Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Ann Rev Nutr. 2003; 23: 171-201.
16. Kijlstra A, Tian Y, Kelly ER et al. Lutein: More than just a filter for blue light. Prog Retin Eye Res. 2012; 31: 303-15.
17. Tian Y, Kijlstra A, Webers CAB et al. Lutein and Factor D: Two intriguing players in the field of age-related macular degeneration. Arch Biochem Biophys. 2015; 572: 49-53.
18. Bian Q, Gao S, Zhou J et al. Lutein and zeaxanthin supplementation reduces photooxidative damage and modulates the expression of inflammation-related genes in retinal pigment epithelial cells. Free Radic Biol Med. 2012; 53: 1298-307.
19. Fung FK, Law BY, Lo AC. Lutein Attenuates Both Apoptosis and Autophagy upon Cobalt (II) Chloride-Induced Hypoxia in Rat Muller Cells. PLoS ONE. 2016; 11: e0167828.
20. Gale CR, Hall NF, Phillips DIW et al. Lutein and Zeaxanthin Status and Risk of Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2003; 44: 2461-5.
21. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA. 2013; 309: 2005-15.
22. Seddon JM, George S, Rosner B. Cigarette Smoking, Fish Consumption, Omega-3 Fatty Acid Intake, and Associations With Age-Related Macular Degeneration The US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol. 2006; 124(7): 995-1001.
23. Seddon JM, Rosner B, Sperduto RD et al. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol. 2001; 119: 1191-9.
24. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004; 11(suppl 1): S56-64.
25. Christen WG, Glynn RJ, Chew EY et al. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women’s Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med. 2009; 169: 335-41.
26. Gopinath B, Flood VM, Rochtchina E et al. Homocysteine, folate, vitamin B-12, and 10-y incidence of age-related macular degeneration. Am J Clin Nutr. 2013; 98(1): 129-35.
27. Christen WG, Glynn RJ, Chew EY et al. Folic Acid, Vitamin B6, and Vitamin B12 in Combination and Agerelated Macular Degeneration in a Randomized Trial of Women. Arch Intern Med. 2009; 169(4): 335-41.
28. Herbert V, Bigaouette J. Call for endorsement of a petition to the Food and Drug Administration to always add vitamin B-12 to any folate fortification or supplement. Am J Clin Nutr. 1997; 65: 572-3.
29. Smailhodzic D, Van Asten F, Blom A et al. Zinc supplementation inhibits complement activation in age-related macular degeneration. PLoS One. 2014; 9(11): e112682.
30. Dharamdasani Detaram H, Mitchell P, Russell J et al. Dietary zinc intake is associated with macular fluid in neovascular age-related macular degeneration. Clin Exp Ophthalmol. 2020; 48(1): 61-8.
31. Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001; 119(10): 1417-36.